PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability

被引：12
|
作者：
Mark, Daniel B. [1 ]
Schulman, Kevin A. [1 ]
机构：
[1] Duke Univ, Med Ctr, Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2017年 / 318卷 / 08期
关键词：
IMPACT;
D O I：
10.1001/jama.2017.8907
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：711 / 712
页数：2
相关论文
共 50 条
  • [31] Evidence for PCSK9 Inhibitors to Date
    不详
    JOURNAL OF CARDIOVASCULAR NURSING, 2018, 33 (02) : 95 - 96
  • [32] Are PCSK9 Inhibitors Cost Effective?
    Korman, Max J.
    Retterstol, Kjetil
    Kristiansen, Ivar Sonbo
    Wisloff, Torbjorn
    PHARMACOECONOMICS, 2018, 36 (09) : 1031 - 1041
  • [33] PCSK9 inhibitors and diabetes risk
    Mueller-Wieland, Dirk
    DIABETOLOGIE UND STOFFWECHSEL, 2018, 13 (02) : 140 - 141
  • [34] PCSK9 Inhibitors and Cardiovascular Events
    Goemann, Iuri M.
    Londero, Thiza M.
    Dora, Jose M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (08): : 773 - 774
  • [35] Neurocognitive Risk With PCSK9 Inhibitors
    Khan, Abdur Rahman
    Riaz, Haris
    Farid, Talha
    Bolli, Roberto
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (19) : 2468 - 2469
  • [36] PCSK9 inhibitors for LDL lowering
    Walsh, Lames P.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (07) : 575 - 577
  • [37] A Comprehensive Review of PCSK9 Inhibitors
    Coppinger, Caroline
    Movahed, Mohammad Reza
    Azemawah, Veronica
    Peyton, Lee
    Gregory, James
    Hashemzadeh, Mehrnoosh
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2022, 27
  • [38] PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
    Vicente-Valor, Juan
    Garcia-Gonzalez, Xandra
    Ibanez-Garcia, Sara
    Duran-Garcia, Maria Esther
    de Lorenzo-Pinto, Ana
    Rodriguez-Gonzalez, Carmen
    Mendez-Fernandez, Irene
    Percovich-Hualpa, Juan Carlos
    Herranz-Alonso, Ana
    Sanjurjo-Saez, Maria
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 146
  • [39] High glucose effects on PCSK9 expression in aortic VSMC: role of PCSK9 inhibitors
    Barale, C.
    Melchionda, E.
    Russo, I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S421 - S421
  • [40] PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
    Paciullo, Francesco
    Momi, Stefania
    Gresele, Paolo
    THROMBOSIS AND HAEMOSTASIS, 2019, 119 (03) : 359 - 367
12345